Penumbra (NYSE:PEN) Hits New 1-Year High – What’s Next?

Penumbra, Inc. (NYSE:PEN)’s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as $352.00 and last traded at $351.5470, with a volume of 1788470 shares changing hands. The stock had previously closed at $313.43.

Penumbra News Summary

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for about $14.5B (reports show ~ $374 per share in cash or a stock alternative), a material takeover premium that typically lifts target share prices. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra provided preliminary Q4 and FY‑2025 results/guidance showing stronger-than-expected revenue (Q4 revenue guidance ~$383.0M–$384.8M vs. consensus ~ $361.9M; FY revenue ~ $1.4B), supporting a higher acquisition valuation. Penumbra preliminary update on Q4 and FY 2025
• Positive Sentiment: Market headlines and premarket movers lists highlighted Penumbra as a top gainer after the deal, amplifying buying interest from momentum and event‑driven traders. Barron’s: S&P 500 Futures Up; Penumbra Leads
• Neutral Sentiment: Press coverage frames the deal as strategic (adds thrombectomy/neurovascular scale to Boston Scientific) — important for long‑term strategic rationale but less immediately material to PEN equity price than the deal terms. Reuters: Boston Scientific to buy Penumbra
• Negative Sentiment: An investor‑rights law firm (Halper Sadeh LLC) opened an investigation into whether the sale is fair to Penumbra shareholders, signaling potential legal scrutiny or shareholder objections that could delay closing or alter terms. Business Wire: Halper Sadeh investigation
• Negative Sentiment: Because part of the consideration can be Boston Scientific stock, moves in BSX’s share price will affect the effective deal value for PEN holders who take stock; early reports note some downward pressure on BSX after the announcement. Investing.com: Penumbra surges, BSX down

Analysts Set New Price Targets

Several equities analysts recently issued reports on PEN shares. BTIG Research reissued a “buy” rating and set a $320.00 price objective on shares of Penumbra in a report on Monday, October 27th. Wall Street Zen raised Penumbra from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research report on Monday, December 29th. William Blair lowered Penumbra to a “market perform” rating in a research note on Thursday. Finally, Truist Financial increased their price target on shares of Penumbra from $312.00 to $370.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $340.40.

Penumbra Stock Performance

The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $13.77 billion, a PE ratio of 84.14, a PEG ratio of 1.84 and a beta of 0.71. The business has a 50 day simple moving average of $300.12 and a 200 day simple moving average of $268.29.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.07. The firm had revenue of $354.69 million for the quarter, compared to the consensus estimate of $340.77 million. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The company’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.85 earnings per share. Equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Activity at Penumbra

In other news, Director Harpreet Grewal sold 186 shares of Penumbra stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $312.64, for a total transaction of $58,151.04. Following the completion of the sale, the director directly owned 8,230 shares in the company, valued at approximately $2,573,027.20. The trade was a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Arani Bose sold 15,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $308.82, for a total value of $4,632,300.00. Following the completion of the transaction, the director directly owned 258,462 shares in the company, valued at approximately $79,818,234.84. The trade was a 5.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 34,144 shares of company stock valued at $10,260,127. 4.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PEN. Royal Bank of Canada boosted its position in Penumbra by 35.8% in the first quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock valued at $5,169,000 after buying an additional 5,092 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Penumbra by 53.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,999 shares of the company’s stock valued at $1,255,000 after acquiring an additional 1,748 shares during the period. Diversified Trust Co boosted its holdings in shares of Penumbra by 33.3% in the 2nd quarter. Diversified Trust Co now owns 8,365 shares of the company’s stock valued at $2,147,000 after acquiring an additional 2,089 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Penumbra by 408.3% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,262 shares of the company’s stock valued at $580,000 after acquiring an additional 1,817 shares during the last quarter. Finally, Park Avenue Securities LLC acquired a new stake in shares of Penumbra in the second quarter worth $408,000. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.